David H. Crean, Ph.D is a Managing Director & Partner at Objective Capital Partners, a middle market investment banking firm located in Southern California, where he leads the firm’s M&A, partnering and capital financing transactions with life science and healthcare clients. Dr. Crean has in excess of 25 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Crean also serves on the Board of Directors for Histogen, Inc. and Talapo Therapeutics, as CEO for CelMatrix Technologies, as business advisor for several early-stage life science companies, is a limited partner with Mesa Verde Venture Partners, and a member of BIOCOM, San Diego Venture Group (SDVG) and Corporate Directors Forum. For his outstanding advisory work in the Life Sciences and Healthcare sector, Dr. Crean was recognized for the 2018 Healthcare Hero, 2017 Thought Leader of the Year and 2017 Advisor of the Year Awards. Dr. Crean is also active in the non-profit sector where he serves in leading Board roles for the Association for Corporate Growth (ACG) San Diego, Solutions for Change, Alzheimer’s Association and Altus Charter Schools of San Diego.
Dr. Crean holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management. Additionally, he holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College.